Literature DB >> 12594595

The use of the activated clotting time for monitoring heparin therapy in critically ill patients.

Jan J De Waele1, Sebastiaan Van Cauwenberghe, Eric Hoste, Dominique Benoit, Francis Colardyn.   

Abstract

OBJECTIVE: To determine the correlation between activated clotting time (ACT) and activated partial thromboplastin time (aPTT) in patients receiving intravenous unfractionated heparin therapy, and the accuracy of the ACT in predicting the level of anticoagulation.
DESIGN: Paired aPTT and ACT measurements were obtained from a convenience sample of critically ill patients requiring intravenous unfractionated heparin. The aPTT was determined in the hospital laboratory and ACT measurements were performed with a portable device.
SETTING: The intensive care unit of Ghent University Hospital, a tertiary care facility with 54 beds. PATIENTS AND PARTICIPANTS: Twenty-eight patients were studied prospectively; a total of 105 paired samples were obtained. The indication for heparin therapy was cerebral ischemia in 8, various cardiac conditions in 10, pulmonary embolism in 3, continuous hemofiltration in 3, and peripheral arterial thrombosis in 4.
RESULTS: There was a significant correlation between aPTT and ACT. Analysis of variance showed a significant difference in ACT between different levels of anticoagulation, aPTT shorter than 60 s (group 1), aPTT 60-90 s (group 2), and aPTT longer than 90 s (group 3): 142+/-16.7 s in group 1 vs. 155+/-29.6 and 192+/-39.1 in groups 2 and 3.
CONCLUSIONS: The correlation between the aPTT and the ACT in this ICU setting is poor; ACT cannot differentiate between low and therapeutic levels of anticoagulation. The use of the ACT for monitoring low to moderate doses of heparin in ICU patients cannot be recommended.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12594595     DOI: 10.1007/s00134-002-1609-7

Source DB:  PubMed          Journal:  Intensive Care Med        ISSN: 0342-4642            Impact factor:   17.440


  16 in total

Review 1.  Management of acute coronary syndromes: acute coronary syndromes without persistent ST segment elevation; recommendations of the Task Force of the European Society of Cardiology.

Authors:  M E Bertrand; M L Simoons; K A Fox; L C Wallentin; C W Hamm; E McFadden; P J de Feyter; G Specchia; W Ruzyllo
Journal:  Eur Heart J       Date:  2000-09       Impact factor: 29.983

Review 2.  Heparin: mechanism of action, pharmacokinetics, dosing considerations, monitoring, efficacy, and safety.

Authors:  J Hirsh; J E Dalen; D Deykin; L Poller
Journal:  Chest       Date:  1992-10       Impact factor: 9.410

3.  A comparison of five devices for the bedside monitoring of heparin therapy.

Authors:  A I O'Neill; C McAllister; C F Corke; J D Parkin
Journal:  Anaesth Intensive Care       Date:  1991-11       Impact factor: 1.669

Review 4.  Activated clotting time versus activated partial thromboplastin time for therapeutic monitoring of heparin.

Authors:  R J Simko; F F Tsung; E J Stanek
Journal:  Ann Pharmacother       Date:  1995-10       Impact factor: 3.154

Review 5.  Deep vein thrombosis and its prevention in critically ill adults.

Authors:  J Attia; J G Ray; D J Cook; J Douketis; J S Ginsberg; W H Geerts
Journal:  Arch Intern Med       Date:  2001-05-28

6.  Bedside monitoring of heparin therapy: comparison of activated clotting time to activated partial thromboplastin time.

Authors:  J S Reiner; K S Coyne; C F Lundergan; A M Ross
Journal:  Cathet Cardiovasc Diagn       Date:  1994-05

Review 7.  A review of the clinical indications for the plasma heparin assay.

Authors:  C D Marci; D Prager
Journal:  Am J Clin Pathol       Date:  1993-05       Impact factor: 2.493

8.  Laboratory monitoring of heparin therapy--the effect of different salts of heparin on the activated partial thromboplastin time.

Authors:  E I Banez; D A Triplett; J Koepke
Journal:  Am J Clin Pathol       Date:  1980-10       Impact factor: 2.493

9.  Heparin monitoring during coronary intervention: activated clotting time versus activated partial thromboplastin time.

Authors:  F C Nath; D W Muller; U Rosenschein; S G Ellis; E J Topol
Journal:  Can J Cardiol       Date:  1993-11       Impact factor: 5.223

10.  A randomized trial comparing activated thromboplastin time with heparin assay in patients with acute venous thromboembolism requiring large daily doses of heparin.

Authors:  M N Levine; J Hirsh; M Gent; A G Turpie; M Cruickshank; J Weitz; D Anderson; M Johnson
Journal:  Arch Intern Med       Date:  1994-01-10
View more
  11 in total

Review 1.  Anticoagulation strategies in continuous renal replacement therapy: can the choice be evidence based?

Authors:  H M Oudemans-van Straaten; J P J Wester; A C J M de Pont; M R C Schetz
Journal:  Intensive Care Med       Date:  2006-02-02       Impact factor: 17.440

2.  Enhanced Photoacoustic Detection of Heparin in Whole Blood via Melanin Nanocapsules Carrying Molecular Agents.

Authors:  Wonjun Yim; Kathryn Takemura; Jiajing Zhou; Jingcheng Zhou; Zhicheng Jin; Raina M Borum; Ming Xu; Yong Cheng; Tengyu He; William Penny; Bill R Miller; Jesse V Jokerst
Journal:  ACS Nano       Date:  2021-12-28       Impact factor: 18.027

3.  Consumption of blood products during mechanical circulatory support in children: comparison between ECMO and a pulsatile ventricular assist device.

Authors:  Brigitte Stiller; Julia Lemmer; Frank Merkle; Vladimir Alexi-Meskishvili; Yuguo Weng; Michael Hübler; Andreas Koster; Thorsten Drews; Peter E Lange; Roland Hetzer
Journal:  Intensive Care Med       Date:  2004-07-22       Impact factor: 17.440

4.  An ex vivo comparison of partial thromboplastin time and activated clotting time for heparin anticoagulation in an ovine model.

Authors:  Zachary B K Berk; Aakash Shah; Wenji Sun; Bartley P Griffith; Zhongjun J Wu
Journal:  Artif Organs       Date:  2021-11-02       Impact factor: 3.094

5.  Role of citrate and other methods of anticoagulation in patients with severe liver failure requiring continuous renal replacement therapy.

Authors:  Josée Bouchard; François Madore
Journal:  NDT Plus       Date:  2008-12-09

6.  Low flow extracorporeal CO2 removal in ARDS patients: a prospective short-term crossover pilot study.

Authors:  Harlinde Peperstraete; Sunny Eloot; Pieter Depuydt; Filip De Somer; Carl Roosens; Eric Hoste
Journal:  BMC Anesthesiol       Date:  2017-11-28       Impact factor: 2.217

7.  Spontaneous ilio-psoas hematomas complicating intensive care unit hospitalizations.

Authors:  Thierry Artzner; Raphaël Clere-Jehl; Malika Schenck; Michel Greget; Hamid Merdji; Pierre De Marini; Nicolas Tuzin; Julie Helms; Ferhat Meziani
Journal:  PLoS One       Date:  2019-02-22       Impact factor: 3.240

Review 8.  Extracorporeal Gas Exchange for Acute Respiratory Distress Syndrome: Open Questions, Controversies and Future Directions.

Authors:  Marco Giani; Simone Redaelli; Antonio Siragusa; Benedetta Fumagalli; Roberto Rona; Giuseppe Foti
Journal:  Membranes (Basel)       Date:  2021-02-28

9.  Antithrombin effect on coagulation and fibrinolytic profiles after living donor liver transplantation: a pilot study.

Authors:  J Kaneko; Y Sugawara; S Tamura; J Togashi; Y Matsui; M Makuuchi
Journal:  Int J Lab Hematol       Date:  2008-12-08       Impact factor: 2.877

Review 10.  Clinical review: Patency of the circuit in continuous renal replacement therapy.

Authors:  Michael Joannidis; Heleen M Oudemans-van Straaten
Journal:  Crit Care       Date:  2007       Impact factor: 9.097

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.